GTx shares fall 65% on Phase III enobosarm data
This article was originally published in Scrip
Executive Summary
GTx saw its market cap reduced from $262.2 million to $90.3 million on 19 August after the Memphis, Tennessee-based company reported that enobosarm for the treatment of muscle wasting in non-small cell lung cancer (NSCLC) patients did not meet the overall criteria for the co-primary responder endpoints in the drug's two Phase III clinical trials.